GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Becton, Dickinson and Co (NYSE:BDXB.PFD) » Definitions » Net Change in Cash

BDXB.PFD (Becton, Dickinson and Co) Net Change in Cash : $-1,650.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Becton, Dickinson and Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Becton, Dickinson and Co's Net Change in Cash for the three months ended in Mar. 2025 was $-66.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was $-1,650.00 Mil.

Becton, Dickinson and Co Net Change in Cash Historical Data

The historical data trend for Becton, Dickinson and Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Becton, Dickinson and Co Net Change in Cash Chart

Becton, Dickinson and Co Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,326.00 -523.00 -1,234.00 321.00 373.00

Becton, Dickinson and Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,161.00 2,090.00 -2,631.00 -1,043.00 -66.00

Becton, Dickinson and Co Net Change in Cash Calculation

Becton, Dickinson and Co's Net Change in Cash for the fiscal year that ended in Sep. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=3797+-5514+2086+4
=373.00

Becton, Dickinson and Co's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=164+-192+-39+1
=-66.00

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,650.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Becton, Dickinson and Co Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Becton, Dickinson and Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Becton, Dickinson and Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Becton, Dickinson and Co (NYSE:BDXB.PFD) » Definitions » Net Change in Cash
Comparable Companies
RMD COO BAX WST ALGN HOLX SOLV ATR AVTR RGEN ISRG XPAR:EL XSWX:ALC TSE:7741 TSE:4543 OCSE:COLO B XPAR:DIM XSWX:STMN NZSE:FPH SZSE:300896
Traded in Other Exchanges
BDX:USA BDX:Mexico 1BDX:Italy 0R19:UK BOX:Germany BDX:Austria
Address
1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
Website
https://www.bd.com
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.